ConductScience.org, home

Paper825035

Synergistic activity of carbenicillin and gentamicin in experimental Pseudomonas bacteremia in neutropenic rats.

Scott RE and 1 other. Antimicrob Agents Chemother, 1976. Cited by 69 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Synergistic activity of carbenicillin and gentamicin in experimental Pseudomonas bacteremia in neutropenic rats. Papers, record 825035. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/825035

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Synergistic activity of carbenicillin and gentamicin in experimental Pseudomonas bacteremia in neutropenic rats.
PubMed
Journal
Antimicrob Agents Chemother
PubMed
Year
1976
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
69
iCite
Relative citation ratio, by iCite
3.29
iCite
Revised in PubMed
2021-05-26
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Scott RER E
2Robson HGH G

Source PubMed

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AgranulocytosisMajor topic
CarbenicillinMajor topic
GentamicinsMajor topic
NeutropeniaMajor topic
Pseudomonas InfectionsMajor topic
SepsisMajor topic
Animals
Drug Synergism
Female
Pseudomonas aeruginosa
Rats
Time Factors

Source PubMed

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
113,880,374Determinants of infection in the peritoneal cavity. I. Response to and fate of Staphylococcus aureus and Staphylococcus albus in the mouse.Yale J Biol Med1962https://conductscience.org/library/papers/13880374PubMed
25,001,622Gentamicin: clinical use with carbenicillin and in-vitro studies with recent isolates of Pseudomonas aeruginosa.J Infect Dis1971https://conductscience.org/library/papers/5001622PubMed
34,372,051Pseudomonas septicemia: incidence, epidemiology, prevention and therapy in patients with advanced cancer.Eur J Cancer (1965)1973https://conductscience.org/library/papers/4372051PubMed
44,372,050Advances in the management of Pseudomonas aeruginosa infections in cancer patients.Eur J Cancer (1965)1973https://conductscience.org/library/papers/4372050PubMed
55,001,620Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin.J Infect Dis1971https://conductscience.org/library/papers/5001620PubMed
64,937,796Carbenicillin therapy for pseudomonas infections.JAMA1971https://conductscience.org/library/papers/4937796PubMed
74,893,148Carbenicillin therapy of gram-negative bacilli infections.Am J Med Sci1969https://conductscience.org/library/papers/4893148PubMed
8816,976Therapy of neutropenic rats infected with Pseudomonas aeruginosa.J Infect Dis1976https://conductscience.org/library/papers/816976PubMed
91,101,822Feasibility of administering aminoglycoside antibiotics by continuous intravenous infusion.Antimicrob Agents Chemother1975https://conductscience.org/library/papers/1101822PubMed
101,159,330Gentamicin sulfate pharmacokinetics: lower levels of gentamicin in blood during fever.J Infect Dis1975https://conductscience.org/library/papers/1159330PubMed
115,164,949Synergy of carbenicillin and gentamicin in experimental infection with Pseudomonas.J Infect Dis1971https://conductscience.org/library/papers/5164949PubMed
124,375,433Interaction of purulent material with antibiotics used to treat Pseudomonas infections.Antimicrob Agents Chemother1974https://conductscience.org/library/papers/4375433PubMed
134,335,448Antibiotics for Pseudomonas aeruginosa sepis: inadequate proof of efficacy.J Infect Dis1971https://conductscience.org/library/papers/4335448PubMed
144,313,764In vitro effects of carbenicillin combined with gentamicin or polymyxin B against Pseudomonas aeruginosa.Appl Microbiol1969https://conductscience.org/library/papers/4313764PubMed
154,322,162Pseudomonas bacteremia in patients with malignant diseases.Am J Med Sci1970https://conductscience.org/library/papers/4322162PubMed
164,213,977Significance of Pseudomonas aeruginosa in the patient with leukemia or lymphoma.J Infect Dis1974https://conductscience.org/library/papers/4213977PubMed
174,213,872Bacteremia due to Pseudomonas aeruginosa complicating neoplastic disease: a progress report.J Infect Dis1974https://conductscience.org/library/papers/4213872PubMed
184,201,634Pseudomonas aeruginosa resistant to carbenicillin and gentamicin. Epidemiologic and clinical aspects in a cancer center.Ann Intern Med1973https://conductscience.org/library/papers/4201634PubMed
194,208,283Comparison of gentamicin, carbenicillin and gentamicin, and carbenicillin in Pseudomonas sepsis in monkeys.Antimicrob Agents Chemother1973https://conductscience.org/library/papers/4208283PubMed
204,202,683Gram-negative infections in cancer. Study of empiric therapy comparing carbenicillin-cephalothin with and without gentamicin.JAMA1974https://conductscience.org/library/papers/4202683PubMed

See all 28 references

Cited by21

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 69 citations.

PMIDTitleJournalYearIn PapersSource
36,421,304Defining Exposure Predictors of Meropenem That Are Associated with Improved Survival for Severe Bacterial Infection: A Preclinical PK/PD Study in Sepsis Rat Model.Antibiotics (Basel)2022https://conductscience.org/library/papers/36421304PubMed
31,589,646Replacing plasma membrane outer leaflet lipids with exogenous lipid without damaging membrane integrity.PLoS One2019https://conductscience.org/library/papers/31589646PubMed
29,463,528
Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.
Antimicrob Agents Chemother2018https://conductscience.org/library/papers/29463528PubMed
28,993,331
Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.
Antimicrob Agents Chemother2017https://conductscience.org/library/papers/28993331PubMed
8,980,762Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model.Antimicrob Agents Chemother1997https://conductscience.org/library/papers/8980762PubMed
6,792,982Comparative in vitro synergistic activity of new beta-lactam antimicrobial agents and amikacin against Pseudomonas aeruginosa and Serratia marcescens.Antimicrob Agents Chemother1981https://conductscience.org/library/papers/6792982PubMed
6,517,544Synergism at clinically attainable concentrations of aminoglycoside and beta-lactam antibiotics.Antimicrob Agents Chemother1984https://conductscience.org/library/papers/6517544PubMed
6,329,087Comparison of azlocillin, ceftizoxime, cefoxitin, and amikacin alone and in combination against Pseudomonas aeruginosa in a neutropenic-site rabbit model.Antimicrob Agents Chemother1984https://conductscience.org/library/papers/6329087PubMed
6,315,424In vitro and in vivo synergy between ceftriaxone and aminoglycosides against Pseudomonas aeruginosa.Eur J Clin Microbiol1983https://conductscience.org/library/papers/6315424PubMed
6,289,731Comparative synergistic activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, combined with tobramycin, against Pseudomonas aeruginosa.Antimicrob Agents Chemother1981https://conductscience.org/library/papers/6289731PubMed
6,282,192In vitro and in vivo studies of three antibiotic combinations against gram-negative bacteria and Staphylococcus aureus.Antimicrob Agents Chemother1981https://conductscience.org/library/papers/6282192PubMed
6,219,619Bactericidal and synergistic activity of moxalactam alone and in combination with gentamicin against Pseudomonas aeruginosa.Antimicrob Agents Chemother1983https://conductscience.org/library/papers/6219619PubMed
3,924,610Use of discriminative models of Pseudomonas aeruginosa bacteremia in granulocytopenic rats for testing antimicrobial efficacy.Eur J Clin Microbiol1985https://conductscience.org/library/papers/3924610PubMed
3,909,952Comparative activities of piperacillin, ceftazidime, and amikacin, alone and in all possible combinations, against experimental Pseudomonas aeruginosa infections in neutropenic rats.Antimicrob Agents Chemother1985https://conductscience.org/library/papers/3909952PubMed
3,107,461Evaluation of combination chemotherapy in a lightly anesthetized animal model of Pseudomonas pneumonia.Antimicrob Agents Chemother1987https://conductscience.org/library/papers/3107461PubMed
2,938,945Synergy of ciprofloxacin and azlocillin in vitro and in a neutropenic mouse model of infection.Eur J Clin Microbiol1986https://conductscience.org/library/papers/2938945PubMed
1,803,987Antimicrobial agent therapy for Pseudomonas aeruginosa.Antimicrob Agents Chemother1991https://conductscience.org/library/papers/1803987PubMed
1,510,412In vivo antibiotic synergism: contribution of animal models.Antimicrob Agents Chemother1992https://conductscience.org/library/papers/1510412PubMed
478,641Efficacy of antimicrobial therapy in experimental rat pneumonia: antibiotic treatment schedules in rats with impaired phagocytosis.Infect Immun1979https://conductscience.org/library/papers/478641PubMed
478,640Efficacy of antimicrobial therapy in experimental rat pneumonia: effects of impaired phagocytosis.Infect Immun1979https://conductscience.org/library/papers/478640PubMed

See all 21 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/825035

GET https://conductscience.org/api/papers/v1/825035/references?page=2